Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Aug 2014

Zou Minjing, Baitei Essa Y, Alzahrani Ali S, BinHumaid Faisal S, Alkhafaji Dania, Al-Rijjal Roua A, Meyer Brian F, Shi Yufei

Abstract excerpt

BACKGROUND: RET/PTC rearrangement, RAS, and BRAF mutations are considered to be mutually exclusive in papillary thyroid carcinoma (PTC). However, although concomitant mutations of RET/PTC, RAS, or BRAF have been reported recently, their significance for tumor progression and survival remains uncl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Paired Box Transcription Factors

Share to PAX8 Transcription Factor

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Cancer, Papillary

Source

Open in PubMed Open full text

Identifiers

PMID: 24798740
DOI: 10.1089/thy.2013.0610
PMCID: PMC4106383

Genes

BRAF
RET
KRAS
NRAS
HRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24798740-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.PMID 24798740Read ↗

Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.Semantic proximity Read ↗

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.Semantic proximity Read ↗

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.Semantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.Semantic proximity Read ↗

BRAF<sup>V600E</sup> Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid CancerSemantic proximity Read ↗

BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.Semantic proximity Read ↗

Oncogenic alterations in papillary thyroid cancers of young patients.Semantic proximity Read ↗

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Semantic proximity Read ↗

BRAF mutation in thyroid cancer.Semantic proximity Read ↗

Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.Semantic proximity Read ↗

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.Semantic proximity Read ↗

Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangementsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.